Previous 10 | Next 10 |
2023-10-26 09:49:41 ET Summary INmune Bio is a phase 2 stage biotech company focusing on Alzheimer's and other diseases with its lead asset, XPro, and its endogenous NK cell activator, INKmune. INmune's XPro has shown promising results in stabilizing Alzheimer's disease and improv...
2023-10-04 17:23:37 ET Summary Alector, Inc. is a clinical stage biotech company with no product income and a limited portfolio. The company focuses on smart development and collaborations with big pharma to compensate for its lack of product income. Alector experienced highs ...
2023-09-25 10:34:25 ET More on Alector Seeking Alpha’s Quant Rating on Alector Financial information for Alector Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript Alector: Immuno-Neurology Innovator But Wait For The Pipeline Success Alector...
2023-09-25 09:59:16 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecuti...
2023-09-14 13:02:36 ET More on Alzheimer's drug developers Cassava Sciences: Insiders Purchasing Stock, Is The Market Still Buying Simufilam? Prothena: Dunn Appointment And Bristol Opt-In Boost Validation Anavex Life Sciences: Multiple CNS Shots On Goal Awaiting Conv...
2023-09-07 14:12:54 ET More on AbbVie, Alector, etc. AbbVie: Proving The Bears Wrong Again As Shares Surged AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued AbbVie: Balance Is Everything AbbVie: Still A Buy According To Buffett's 10xEBT Rule Ab...
2023-09-07 11:04:48 ET More on Lilly, Novo, etc. Novo Nordisk: Super Focused Pharma Company For The Long Run Novo Nordisk: Strong Fundamentals Meet Technical Uptrends Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Se...
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has completed enrollment in INVOKE-2, the Phase 2 clinical trial of AL002. INVOKE-2 is evaluating the safety an...
2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...
2023-08-04 09:45:22 ET Alector, Inc. (ALEC) Q2 2023 Results Conference Call August 03, 2023 04:30 PM ET Company Participants Katie Hogan - Senior Director of Corporate Communication and Investor Relations Dr. Arnon Rosenthal - Co-Founder and CEO Dr. Sara Kenkare-...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...